Cryofocus Medtech (Shanghai) Co (HKSE:06922) ROCE % : -37.35% (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cryofocus Medtech (Shanghai) Co's annualized ROCE % for the quarter that ended in Jun. 2023 was -37.35%.

Cryofocus Medtech (Shanghai) Co ROCE % Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co ROCE % Chart

Cryofocus Medtech (Shanghai) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-313.13

-99.84

-47.94

-46.12

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-	-41.96	-54.56	-37.35	-56.22

Cryofocus Medtech (Shanghai) Co ROCE % Calculation

Cryofocus Medtech (Shanghai) Co's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-131.47	/	( ( (283.701 - 34.639)	+	(350.495 - 51.072) )	/ 2 )
	=	-131.47	/	( (249.062	+	299.423)	/ 2 )
	=	-131.47	/	274.2425
	=	-47.94 %

Cryofocus Medtech (Shanghai) Co's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-103.022	/	( ( (350.495 - 51.072)	+	(280.749 - 28.519) )	/ 2 )
	=	-103.022	/	( ( 299.423	+	252.23 )	/ 2 )
	=	-103.022	/	275.8265
	=	-37.35 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cryofocus Medtech (Shanghai) Co ROCE % Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120

Website

https://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines